Butyrate

Are We What We Eat? Impact of Diet on the Gut–Brain Axis in Parkinson’s Disease

Butyrate, Diet and Exercise, Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis, Parkinson's Disease, Pre-PD, Probiotics, Prebiotics and Symbiotics /

Parkinson’s disease is characterized by motor and non-motor symptoms, such as defects in the gut function, which may occur before the motor symptoms. To date, there are therapies that can improve these symptoms, but there is no cure to avoid the development or exacerbation of this disorder. Dysbiosis of gut microbiota could have a crucial […]

Are We What We Eat? Impact of Diet on the Gut–Brain Axis in Parkinson’s Disease Read More »

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Butyrate, Gut Microbiota, Parkinson's Disease, Short Chain Fatty Acids /

Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Read More »

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients

Butyrate, Constipation, Gut Microbiota, Parkinson's Disease, Short Chain Fatty Acids /

Background and Objectives: Short-chain fatty acids (SCFAs) are gut microbial metabolitesthat promote the disease process in a rodent model of Parkinson’s disease (PD), but fecallevels of SCFAs in PD patients are reduced. Simultaneous assessments of fecal and plasmaSCFA levels, and their inter-relationships with the PD disease process are scarce. We aimedto compare fecal and plasma

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients Read More »

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation

Butyrate, Constipation, Pre-PD, Short Chain Fatty Acids /

A variety of opinions exist on the potential of probiotics to provide relief from chronic constipation with much focus placed on their mechanism of action and causes of heterogeneity in the results of different studies. We aimed to determine the efficacy and safety of ingesting Bifidobacterium bifidum (B. bifidum) CCFM16 for 28 days to relieve

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation Read More »

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Autonmic nervous system, Biomarkers, Butyrate, Gut Dysbiosis, Gut Permeability / Leaky Gut, Parkinson's Disease, Short Chain Fatty Acids /

Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Read More »

Gut Microbiota-Brain Interaction with Special Reference to Alzheimer’s Disease

Butyrate, Gut Dysbiosis, Gut Microbiota, Gut-Brain axis, Parkinson's Disease, Pre-PD /

Gut microbiota is showing and raising evidence that the dynamic changes in the gut microorganism can influence physiology and behavior of brain. Dysbiosis or dysbacteriosis is a condition of microbial imbalance inside the intestinal microbiome. It has been associated with disorders of intestinal and extra‐intestinal such as inflammatory bowel disease and other multiple diseases like

Gut Microbiota-Brain Interaction with Special Reference to Alzheimer’s Disease Read More »

S889 Effects of Etoh on Human Intestinal Epithelial and Microvascular Endothelial Cells (HIMEC) in Patients With Inflammatory Bowel Disease: An in-vitro Exploration

Butyrate, Gut Dysbiosis /

Ethanol (EtOH) is associated with IBD flares, but the exact mechanisms are not well-known. Gut dysbiosis and depleted luminal butyrate are both linked with IBD and EtOH exposure. We tested our hypothesis that EtOH-induced gut dysbiosis and depleted butyrate levels disrupt intestinal epithelial junctional proteins which facilitates ethanol and endotoxin interaction with intestinal microvascular endothelial

S889 Effects of Etoh on Human Intestinal Epithelial and Microvascular Endothelial Cells (HIMEC) in Patients With Inflammatory Bowel Disease: An in-vitro Exploration Read More »

Neuroprotection of chicoric acid in a mouse model of Parkinson’s disease involves gut microbiota and TLR4 signaling pathway

Butyrate, Gut Dysbiosis, Gut Permeability / Leaky Gut, Gut-Brain axis, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

Chicoric acid (CA), a polyphenolic acid obtained from chicory and purple coneflower (Echinacea purpurea), has been regarded as nutraceutical to combat inflammation, virus and obesity. Parkinson’s Disease (PD) is a common neurodegenerative disorder, and microbiota-gut-brain axis might be the potential mechanism in the pathogenesis and development of PD. The results here demonstrated that oral pretreatments

Neuroprotection of chicoric acid in a mouse model of Parkinson’s disease involves gut microbiota and TLR4 signaling pathway Read More »

Sodium butyrate attenuates rotenone-induced toxicity by activation of autophagy through epigenetically regulating PGC-1α expression in PC12 cells

Autophagy, Butyrate, Parkinson's Disease, Short Chain Fatty Acids /

Short-chain fatty acids (SCFAs) are considered the key molecular link between gut microbiota and pathogenesis of Parkinson’s disease (PD). However, the role of SCFAs in PD pathogenesis is controversial. Autophagy is important for the degradation of α-synuclein, which is critical to the development of PD. However, whether SCFAs can regulate autophagy in PD remains unknown.

Sodium butyrate attenuates rotenone-induced toxicity by activation of autophagy through epigenetically regulating PGC-1α expression in PC12 cells Read More »

Regulation of common neurological disorders by gut microbial metabolites

Butyrate, Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis, Short Chain Fatty Acids /

The gut is connected to the CNS by immunological mediators, lymphocytes, neurotransmitters, microbes and microbial metabolites. A mounting body of evidence indicates that the microbiome exerts significant effects on immune cells and CNS cells. These effects frequently result in the suppression or exacerbation of inflammatory responses, the latter of which can lead to severe tissue

Regulation of common neurological disorders by gut microbial metabolites Read More »